Clinical Trials on Gram Negative Meningitis

Total 6634 results

Novartis Vaccines
Novartis

Completed

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Meningococcal Disease | Meningococcal Meningitis

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Meningococcal Disease | Meningococcal Meningitis

Australia, Canada
Novartis Vaccines

Completed

Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
CanSino Biologics Inc.

Recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
CanSino Biologics Inc.

Recruiting

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Epidemic Meningitis

China
Novartis Vaccines
GlaxoSmithKline

Completed

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Meningococcal Meningitis | Meningoccocal Disease

Hungary, Spain
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis
Novartis Vaccines

Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Meningococcal Disease | Meningococcal Meningitis

Poland
Novartis Vaccines

Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Meningococcal Disease | Meningococcal Meningitis

Spain, Brazil, Hungary, Peru
Novartis Vaccines
Novartis

Completed

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

Meningococcal Disease | Meningococcal Meningitis

Italy
Epicentre
University of Oslo; Norwegian Institute of Public Health; Medecins Sans Frontieres...

Completed

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Infections, Meningococcal | Meningitis, Meningococcic

Norway, Uganda
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
University Hospital Southampton NHS Foundation...
University of Southampton

Unknown

A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 (Lac-3)

Meningitis, Meningococcal

United Kingdom
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guangxi Center for Disease Control... and other collaborators

Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Meningitis, Meningococcal

China
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants

Meningitis, Meningococcal
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
GlaxoSmithKline

Active, not recruiting

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Meningitis, Meningococcal

Germany, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Meningitis, Meningococcal

Korea, Republic of, Mexico, Russian Federation, Thailand
Serum Institute of India Pvt. Ltd.
PATH

Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Meningitis, Meningococcal

Mali
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Meningitis, Meningococcal

Spain, Finland, Estonia, South Africa, Brazil, Mexico, Russian Federation, France, Turkey
GlaxoSmithKline

Completed

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Meningitis, Meningococcal

Czechia
Epicentre
Medecins Sans Frontieres, Netherlands

Completed

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Meningitis, Meningococcal

Niger
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
Center for Vaccine Development - Mali
University College, London; University of Oxford; Public Health England; University... and other collaborators

Recruiting

A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults

Meningitis, Meningococcal

Mali
Epicentre
Medecins Sans Frontieres, Netherlands

Withdrawn

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Meningitis, Meningococcal

Niger
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Meningitis, Meningococcal

Australia
Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
GlaxoSmithKline

Completed

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Meningitis, Meningococcal

Australia, Germany
University Hospital, Clermont-Ferrand

Unknown

Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration

Pseudomonas Aeruginosa Meningitis
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Meningitis, Meningococcal

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
Novartis Vaccines

Completed

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Meningococcal Disease | Meningococcal Meningitis

Italy
Novartis
Novartis Vaccines

Completed

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Meningococcal Meningitis

United States, Italy
St George's, University of London

Unknown

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive)

HIV Infections | Hiv | Meningitis, Meningococcal

United Kingdom
University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Meningitis | Meningococcal Infections

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.

Gram-Negative Bacterial Infections | Gram-Positive Bacterial Infections | Meningitis | Neurosurgery | Ventriculitis | Intracranial Infections
Merck Sharp & Dohme LLC

Completed

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Meningitis, Meningococcal | Rotavirus Infections
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia

3

Subscribe